Product Name :
Hydroxypyruvic acid lithium hydrate
Description:
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.
CAS:
209728-15-4
Molecular Weight:
128.01
Formula:
C3H5LiO5
Chemical Name:
(hydrogeniooxy)hydrogen; lithio 3-hydroxy-2-oxopropanoate
Smiles :
O.[Li]OC(=O)C(=O)CO
InChiKey:
YHTVWBANKNBEKJ-UHFFFAOYSA-M
InChi :
InChI=1S/C3H4O4.Li.H2O/c4-1-2(5)3(6)7;;/h4H,1H2,(H,6,7);;1H2/q;+1;/p-1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.|Product information|CAS Number: 209728-15-4|Molecular Weight: 128.01|Formula: C3H5LiO5|Chemical Name: (hydrogeniooxy)hydrogen; lithio 3-hydroxy-2-oxopropanoate|Smiles: O.{{Gadopentetate dimeglumine} site|{Gadopentetate dimeglumine} Biological Activity|{Gadopentetate dimeglumine} Data Sheet|{Gadopentetate dimeglumine} supplier|{Gadopentetate dimeglumine} Cancer} [Li]OC(=O)C(=O)CO|InChiKey: YHTVWBANKNBEKJ-UHFFFAOYSA-M|InChi: InChI=1S/C3H4O4.{{Neflamapimod} site|{Neflamapimod} Autophagy|{Neflamapimod} Biological Activity|{Neflamapimod} Data Sheet|{Neflamapimod} supplier|{Neflamapimod} Epigenetic Reader Domain} Li.PMID:24761411 H2O/c4-1-2(5)3(6)7;;/h4H,1H2,(H,6,7);;1H2/q;+1;/p-1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|Hydroxypyruvic acid (lithium hydrate) (intravenous injection; 100 mg/ml; slowly over 10 min) increases the 5-h urinary oxalate and glycolate excretion to 0.68% (6.56 μmol) and 0.53% (5.10 μmol) in control rats, in addition, it increases to 2.43% (23.36 μmol) and 0.79% (7.59 μmol) of the dose in the vitamin-B6-deficient rats.|Products are for research use only. Not for human use.|